The complex landscape of non-coding RNAs in olaparib response and resistance
Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have revolutionized the treatment of cancers with deficiencies in homologous recombination repair (HRR), most notably those with BRCA1/2 mutations. However, the clinical efficacy of olaparib is often limited by the development of both...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-01-01
|
| Seri Bilgileri: | Cancer Treatment and Research Communications |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2468294226001255 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|